Background <p>The effectiveness of immunotherapies against glioblastoma (GB) remains limited. A major obstacle in advancing new strategies is the reliance on non-autologous systems, which do not accurately mimic the true extent of inter-patient heterogeneity in both immune responses and tumor susceptibility. This often leads to misleading conclusions about therapeutic efficacy and targetability.</p> Methods <p>In this study, we addressed this critical…
Autologous profiling reveals inter-patient heterogeneity in V{delta}2+{gamma}{delta}TIL responses to glioblastoma driven by extracellular matrix-BTN3A axis
Journal for ImmunoTherapy of Cancer | | Nicolasen, M. J. T., Gatti, L. C., Gasull-Celades, L., Brazda, P., Botas, M., Zawal, D., van Vliet, E. J., Cleven, A., Sebestyen, Z., Robe, P. A., Beringer, D. X., Kuball, J.
Topics: brain-cancer, cervical-cancer, research
Read the full article at Journal for ImmunoTherapy of Cancer